Decheng Capital

Decheng Capital is a global life sciences investment firm established in 2012 that provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with strong market presence. The firm manages $2.1 billion in assets under management and focuses on identifying and nurturing companies across biotechnology, diagnostics, medical devices, and digital health sectors. With offices in Silicon Valley, New York, and Shanghai, Decheng Capital leverages its global presence to capitalize on the rapid growth of the healthcare industry and breakthroughs in life science research.

Founded in 2012, Decheng Capital was established to bridge the gap between innovative life science research and commercial success. The firm's leadership team includes founder and Managing Director Min Cui, along with Managing Directors Victor Tong Jr. and Peter Colabuono, supported by partners including Dayton Misfeldt, Tony Tong, and Y. Katherine Xu. The team combines deep expertise in venture capital, life sciences, and healthcare strategy, drawing on relationships with prestigious limited partners worldwide to fuel investment activities.

Decheng Capital's portfolio demonstrates significant success in building and scaling life science companies. Portfolio companies have achieved multiple successful exits through initial public offerings, including 3SBio (HKSE: 1530, 2015), Adaptive Biotechnologies (NASDAQ: ADPT, 2019), Arcus Biosciences (NASDAQ: RCUS, 2018), Invitae (NASDAQ: NVTA, 2016), Aadi Bioscience (NASDAQ: AADI, 2021), Terns Pharmaceuticals (NASDAQ: TERN, 2021), Soleran (NASDAQ: SLRN, 2023), and Cstone Pharmaceuticals (NASDAQ: CGON, 2024). Additionally, numerous portfolio companies have been acquired by major pharmaceutical and healthcare companies including Eli Lilly, Vertex, Roche, Illumina, Merck, Regeneron, and Becton Dickinson, demonstrating the firm's ability to identify and develop valuable healthcare innovations.

The firm maintains a disciplined investment approach focused on companies with transformative potential in life sciences. Decheng Capital's portfolio spans over 70 companies across biopharma, diagnostics, medical devices, and healthcare technology sectors. The firm provides not only capital but also strategic support and post-investment value-added services to help entrepreneurs and scientists build legendary companies. With a track record of successful exits and a robust pipeline of portfolio companies, Decheng Capital has established itself as a preferred partner for entrepreneurs, world-class scientists, and strategic partners in the global life sciences ecosystem.